Background and purpose
To investigate the anal wall (Awall) sparing effect of an endorectal balloon (ERB) in 3D conformal radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT) for prostate cancer.
Materials and methods
In 24 patients with localized prostate carcinoma, two planning CT-scans were performed: with and without ERB. A prostate planning target volume (PTV) was defined, and the Awall was delineated, using two different methods. Three-field and 4-field 3D-CRT plans, and IMRT plans were generated with a prescription dose of 78 Gy. In 144 treatment plans, the minimum dose (Dmin), maximum dose (Dmax), and mean dose (Dmean) to the Awall were calculated, as well as the Awall volumes exposed to doses ranging from ⩾20 Gy to ⩾70 Gy (V20 − V70, respectively).
In the 3D-CRT plans, an ERB significantly reduced Dmean, Dmax, and V30 − V70. For IMRT all investigated dose parameters were significantly reduced by the ERB. The absolute reduction of Dmean was 12 Gy in 3D-CRT and was 7.5 Gy in IMRT for both methods of Awall delineation.
Application of an ERB showed a significant Awall sparing effect in both 3D-CRT and IMRT. This may lead to reduced late anal toxicity in prostate radiotherapy.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Radiotherapy and Oncology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial.Int J Radiat Oncol Biol Phys. 2002; 53: 1097-1105
- Dose–response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.J Clin Oncol. 2006; 24: 1990-1996
- Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial.Lancet Oncol. 2007; 8: 475-487
- The association of treatment-related symptoms with quality-of-life outcomes for localized prostate carcinoma patients.Cancer. 2002; 94: 862-871
- Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial.Radiother Oncol. 2004; 73: 1-9
- Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer.Int J Radiat Oncol Biol Phys. 2006; 64: 1151-1161
- Association of anorectal dose–volume histograms and impaired fecal continence after 3D conformal radiotherapy for carcinoma of the prostate.Radiother Oncol. 2003; 69: 209-214
- Dose–volume histograms associated to long-term colorectal functions in patients receiving pelvic radiotherapy.Radiother Oncol. 2005; 74: 203-210
- Toward a definition of a threshold for harmless doses to the anal-sphincter region and the rectum.Int J Radiat Oncol Biol Phys. 2005; 61: 1035-1044
- Gastrointestinal toxicity and its relation to dose distributions in the anorectal region of prostate cancer patients treated with radiotherapy.Int J Radiat Oncol Biol Phys. 2005; 61: 1011-1018
- The influence of a rectal balloon tube as internal immobilization device on variations of volumes and dose–volume histograms during treatment course of conformal radiotherapy for prostate cancer.Int J Radiat Oncol Biol Phys. 2002; 52: 91-100
- Rectal dose sparing with a balloon catheter and ultrasound localization in conformal radiation therapy for prostate cancer.Radiother Oncol. 2003; 67: 285-294
- Rectal wall sparing by dosimetric effect of rectal balloon used during intensity-modulated radiation therapy (IMRT) for prostate cancer.Med Dosim. 2005; 30: 25-30
- Rectal wall sparing effect of three different endorectal balloons in 3D conformal and IMRT prostate radiotherapy.Int J Radiat Oncol Biol Phys. 2005; 63: 565-576
- Class solutions for conformal external beam prostate radiotherapy.Int J Radiat Oncol Biol Phys. 2003; 55: 1109-1120
- Dose–response relations for anal sphincter regarding fecal leakage and blood or phlegm in stools after radiotherapy for prostate cancer. Radiobiological study of 65 consecutive patients.Strahlenther Onkol. 2005; 181: 293-306
- Anal canal anatomy showed by three-dimensional anorectal ultrasonography.Surg Endosc. 2007; 21: 2207-2211
- Dose–wall histograms and normalized dose–surface histograms for the rectum: a new method to analyze the dose distribution over the rectum in conformal radiotherapy.Int J Radiat Oncol Biol Phys. 1999; 45: 1073-1080
- Reduced late rectal mucosal changes after prostate three-dimensional conformal radiotherapy with endorectal balloon, as observed in repeated endoscopy.Int J Radiat Oncol Biol Phys. 2007; 67: 799-811
- Radiation-induced sequelae affecting the continence organ: incidence, pathogenesis, and treatment.Dis Colon Rectum. 2007; 50: 1466-1474
- Anorectal function after three- versus two-dimensional radiation therapy for carcinoma of the prostate.Int J Radiat Oncol Biol Phys. 2009; 73: 46-52
- Physiologic changes of the anorectum after pelvic radiotherapy for the treatment of prostate and bladder cancer.Dis Colon Rectum. 2003; 46: 1182-1188
- Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control.Radiother Oncol. 2007; 82: 160-166
- Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.Int J Radiat Oncol Biol Phys. 2008; 70: 1124-1129
Published online: June 12, 2009
Accepted: May 17, 2009
Received in revised form: May 12, 2009
Received: October 23, 2008
☆Presented in the 9th Biennial ESTRO meeting on Physics and Radiation Technology for Clinical Radiotherapy, September 8–13, 2007, Barcelona, Spain.
© 2009 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.